Cargando…

Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire

OBJECTIVES: Treatment of oral mucositis (OM) is challenging. In order to develop and test useful treatment approaches, the development of reliable, reproducible and simpler methods than are currently available for assessment of OM is important. A Patient-Reported Oral Mucositis Symptom (PROMS) scale...

Descripción completa

Detalles Bibliográficos
Autores principales: Gussgard, Anne Margrete, Hope, Andrew J., Jokstad, Asbjorn, Tenenbaum, Howard, Wood, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948915/
https://www.ncbi.nlm.nih.gov/pubmed/24614512
http://dx.doi.org/10.1371/journal.pone.0091733
_version_ 1782306855727398912
author Gussgard, Anne Margrete
Hope, Andrew J.
Jokstad, Asbjorn
Tenenbaum, Howard
Wood, Robert
author_facet Gussgard, Anne Margrete
Hope, Andrew J.
Jokstad, Asbjorn
Tenenbaum, Howard
Wood, Robert
author_sort Gussgard, Anne Margrete
collection PubMed
description OBJECTIVES: Treatment of oral mucositis (OM) is challenging. In order to develop and test useful treatment approaches, the development of reliable, reproducible and simpler methods than are currently available for assessment of OM is important. A Patient-Reported Oral Mucositis Symptom (PROMS) scale was assessed in patients with head and neck cancer to determine if the patient-reported OM experience, as determined by using the PROMS scale, correlate with OM assessed by clinician-based scoring tools. MATERIALS AND METHODS: Fifty patients with head and neck cancer and undergoing radiotherapy consented to participate. They were examined before cancer treatment and twice weekly during 6–7 weeks of therapy and once 4–6 weeks after therapy. Signs of OM were evaluated using the 3 clinician-based scoring tools; NCI-CTCAE v.3, the OMAS criteria and the Total VAS-OMAS. The participants' OM experiences were recorded using PROMS-questionnaires consisting of 10 questions on a visual analogue scale. Spearman rank correlation test were applied between the PROMS scale values and the clinician-determined scores. Repeated measures mixed linear models were applied to appraise the strengths of correlation at the different time points throughout the observation period. RESULTS: Thirty-three participants completed all stages of the study. The participant experience of OM using the PROMS scale demonstrates good correlations (Spearman's Rho 0.65–0.78, p<0.001) with the clinician-determined scores on the group level over all time points and poor to good correlations (Spearman's Rho -0.12–0.70, p<0.001) on the group level at different time points during and after therapy. When mouth opening was problematic, i.e. during the 6(th) and 7(th) week after commencing cancer treatment, the Spearman's Rho varied between 0.19 and 0.70 (p<0.001). CONCLUSION: Patient experience of OM, as reported by the PROMS scale may be a feasible substitute for clinical assessment in situations where patients cannot endure oral examinations.
format Online
Article
Text
id pubmed-3948915
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39489152014-03-13 Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire Gussgard, Anne Margrete Hope, Andrew J. Jokstad, Asbjorn Tenenbaum, Howard Wood, Robert PLoS One Research Article OBJECTIVES: Treatment of oral mucositis (OM) is challenging. In order to develop and test useful treatment approaches, the development of reliable, reproducible and simpler methods than are currently available for assessment of OM is important. A Patient-Reported Oral Mucositis Symptom (PROMS) scale was assessed in patients with head and neck cancer to determine if the patient-reported OM experience, as determined by using the PROMS scale, correlate with OM assessed by clinician-based scoring tools. MATERIALS AND METHODS: Fifty patients with head and neck cancer and undergoing radiotherapy consented to participate. They were examined before cancer treatment and twice weekly during 6–7 weeks of therapy and once 4–6 weeks after therapy. Signs of OM were evaluated using the 3 clinician-based scoring tools; NCI-CTCAE v.3, the OMAS criteria and the Total VAS-OMAS. The participants' OM experiences were recorded using PROMS-questionnaires consisting of 10 questions on a visual analogue scale. Spearman rank correlation test were applied between the PROMS scale values and the clinician-determined scores. Repeated measures mixed linear models were applied to appraise the strengths of correlation at the different time points throughout the observation period. RESULTS: Thirty-three participants completed all stages of the study. The participant experience of OM using the PROMS scale demonstrates good correlations (Spearman's Rho 0.65–0.78, p<0.001) with the clinician-determined scores on the group level over all time points and poor to good correlations (Spearman's Rho -0.12–0.70, p<0.001) on the group level at different time points during and after therapy. When mouth opening was problematic, i.e. during the 6(th) and 7(th) week after commencing cancer treatment, the Spearman's Rho varied between 0.19 and 0.70 (p<0.001). CONCLUSION: Patient experience of OM, as reported by the PROMS scale may be a feasible substitute for clinical assessment in situations where patients cannot endure oral examinations. Public Library of Science 2014-03-10 /pmc/articles/PMC3948915/ /pubmed/24614512 http://dx.doi.org/10.1371/journal.pone.0091733 Text en © 2014 Gussgard et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gussgard, Anne Margrete
Hope, Andrew J.
Jokstad, Asbjorn
Tenenbaum, Howard
Wood, Robert
Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title_full Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title_fullStr Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title_full_unstemmed Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title_short Assessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaire
title_sort assessment of cancer therapy-induced oral mucositis using a patient-reported oral mucositis experience questionnaire
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948915/
https://www.ncbi.nlm.nih.gov/pubmed/24614512
http://dx.doi.org/10.1371/journal.pone.0091733
work_keys_str_mv AT gussgardannemargrete assessmentofcancertherapyinducedoralmucositisusingapatientreportedoralmucositisexperiencequestionnaire
AT hopeandrewj assessmentofcancertherapyinducedoralmucositisusingapatientreportedoralmucositisexperiencequestionnaire
AT jokstadasbjorn assessmentofcancertherapyinducedoralmucositisusingapatientreportedoralmucositisexperiencequestionnaire
AT tenenbaumhoward assessmentofcancertherapyinducedoralmucositisusingapatientreportedoralmucositisexperiencequestionnaire
AT woodrobert assessmentofcancertherapyinducedoralmucositisusingapatientreportedoralmucositisexperiencequestionnaire